Compare Novo Nordisk A/S (NVO) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tyson Foods, Inc. — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Tyson Foods, Inc. trades at $53.43 (market cap $18.41B). The key difference: Novo Nordisk A/S is far larger — about 9× Tyson Foods, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Tyson Foods, Inc. for 76 Days on average.
| NVO | TSN | |
|---|---|---|
Market Cap | $165.31B | $18.41B |
Volume | 11,432,838 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $68.75 |
52-Week Low | $35.29 | $50.47 |
Typical Hold Time | 116 Days | 76 Days |
Enterprise Value | $179.56B | $25.68B |
Dividend Yield | 4.71% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Tyson Foods (TSN) trades at $52.34, up 1.24% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported revenue of $54.44 billion in 2025, with a net income margin of 1.03%, while recent earnings show two beats and one miss. Analysts maintain a consensus buy rating with a $65.40 price target, but news highlights challenges in the beef segment and ongoing securities investigations.
The outlook for TSN is cautiously optimistic, supported by analyst confidence and dividend stability, but risks include margin pressure from beef losses, legal scrutiny, and volatile cash flows. The stock's valuation at a P/E of 32.31 appears elevated relative to modest profitability, requiring careful monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
